Patients with recurrent high grade and/or muscle-invasive bladder cancer and concomitant upper urinary tract disease, e.g. urothelial tumors or afunctional hydronephrotic kidneys, may be candidates for simultaneous laparoscopic cystectomy and nephroureterectomy.
(UroToday.com) The European Society of Medical Oncology (ESMO) 2021 vannual meeting’s prostate cancer session included a presentation by Dr. Dana Rathkopf discussing the trial concept and design of SAABR, a single arm phase 2 study of abiraterone + atezolizumab + GnRH analog with stereo body radiotherapy (SBRT) in men with metastatic hormone sensitive prostate cancer (mHSPC). […]
(UroToday.com) Following presentations from Dr. Sadeghi on the role of pembrolizumab and sEphB4-HAS in patients with previously treated metastatic urothelial carcinoma and from Dr. Pfister on the role of ddMVAC as neoadjuvant chemotherapy in those with muscle-invasive disease, Dr. Enrique Grande provided an invited discussion to contextualize these papers in the Proffered Paper session of the […]
(UroToday.com) In the Proffered Paper session of the European Society for Medical Oncology (ESMO) Annual Congress focusing on non-prostate cancer genitourinary tumors, Dr. Sadeghi presented a phase II trial of the combination of pembrolizumab (P) and sEphB4-HSA (B4) in patients previously treated for metastatic urothelial carcinoma (mUC).
(UroToday.com) In the Proffered Paper session of the European Society for Medical Oncology (ESMO) Annual Congress focusing on non-prostate cancer genitourinary tumors, Dr. Pfister presented results of the GETUG/AFU VESPER V05 phase III trial assessing dose dense Methotrexate, Vinblastine, Doxorubicin and Cisplatin (dd-MVAC) compared to Gemcitabine and Cisplatin (GC) as perioperative chemotherapy for patients with muscle-invasive […]
(UroToday.com) The European Society of Medical Oncology (ESMO) 2021 annual meeting’s prostate cancer session included a presentation by Dr. John Shen discussing apalutamide for advanced prostate cancer in older patients. In TITAN and SPARTAN, apalutamide added to continuous androgen deprivation therapy (ADT) improved PSA response, radiographic progression-free survival (rPFS), metastasis-free survival (MFS), and overall survival (OS) […]
(UroToday.com) The European Society of Medical Oncology (ESMO) 2021 annual meeting’s prostate cancer session included a presentation by Dr. Emmanuel S. Antonarakis discussing updated results of KEYNOTE-199 with four years of follow-up assessing pembrolizumab monotherapy for docetaxel-pretreated mCRPC. KEYNOTE-199 is a multi-cohort phase II study to evaluate pembrolizumab in mCRPC with previous analyses of three cohorts […]
(UroToday.com) The European Society of Medical Oncology (ESMO) 2021 annual meeting’s prostate cancer session included a presentation by Dr. Christian Gratzke discussing the time course profile of adverse events with darolutamide in the ARAMIS phase 3 trial. Darolutamide is a structurally distinct and highly potent androgen-receptor inhibitor that improved metastasis-free survival by almost 2 years and […]
(UroToday.com) The European Society of Medical Oncology (ESMO) 2021 annual meeting’s prostate cancer session included a presentation by Dr. Neeraj Agarwal discussing the TALAPRO-3 trial concept and design, a phase 3 trial assessing enzalutamide plus talazoparib versus placebo plus enzalutamide in men with DDR gene mutated metastatic castration-sensitive prostate cancer. Treatment for metastatic castration-sensitive prostate cancer […]
(UroToday.com) The European Society of Medical Oncology (ESMO) 2021 annual meeting’s prostate cancer session included a presentation by Dr. Brian Gonzalez discussing patient-reported outcomes in prostate cancer patients receiving prostate-specific membrane antigen (PSMA) radionuclide therapy. PSMA targeted radionuclide therapy is a promising investigational therapy for patients with progressive metastatic castration-resistant prostate cancer (mCRPC), conjugating a radionuclide […]
